PAPER Eiriz MF, Grade S, Rosa A, Xapelli S, Bernardino L, Agasse F, Malva JO
SEARCH RESULTS
329930 RESULTS
PAPER Hodé Y, Benyamina A, Arbus C, Reimold M
Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET).
Psychopharmacology (Berl). 2011 Oct;217(3):315-21. PubMed: 21479533PAPER Hill SE, Miti T, Richmond T, Muschol M
Spatial extent of charge repulsion regulates assembly pathways for lysozyme amyloid fibrils.
PLoS One. 2011;6(4):e18171. PubMed: 21483680PAPER
Brain changes may develop early in people with Alzheimer's risk marker. Changes in brain activity appear to occur before amyloid plaques emerge in people with a form of the APOE4 gene.
Cell Death Differ. 2011 Sep;18(9):1521-30. PubMed: 21476240PAPER
Alzheimer's drug proves ineffective for delirium.
CNS Drugs. 2011 May;25(5):425-33. PubMed: 21476248PAPER Herrmann N, Cappell J, Eryavec GM, Lanctôt KL
Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
CNS Drugs. 2011 May;25(5):425-33. PubMed: 21476613PAPER López-Tobón A, Castro-Álvarez JF, Piedrahita D, Boudreau RL, Gallego-Gómez JC, Cardona-Gómez GP
Silencing of CDK5 as potential therapy for Alzheimer's disease.
Rev Neurosci. 2011;22(2):143-52. PubMed: 21476938PAPER Saura CA, Valero J
The role of CREB signaling in Alzheimer's disease and other cognitive disorders.
Rev Neurosci. 2011;22(2):153-69. PubMed: 21476939PAPER Darby D, Brodtmann A, Woodward M, Budge M, Maruff P
Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease.
Int Psychogeriatr. 2011 Apr 11;:1-10. PubMed: 21477408PAPER de Rover M, Pironti VA, McCabe JA, Acosta-Cabronero J, Arana FS, Morein-Zamir S, Hodges JR, Robbins TW, Fletcher PC, Nestor PJ, Sahakian BJ
Hippocampal dysfunction in patients with mild cognitive impairment: a functional neuroimaging study of a visuospatial paired associates learning task.
Neuropsychologia. 2011 Jun;49(7):2060-70. PubMed: 21477602PAPER Ray B, Gaskins DL, Sajdyk TJ, Spence JP, Fitz SD, Shekhar A, Lahiri DK
Restraint stress and repeated corticotrophin-releasing factor receptor activation in the amygdala both increase amyloid-β precursor protein and amyloid-β peptide but have divergent effects on brain-derived neurotrophic factor and pre-synaptic proteins in
Neuroscience. 2011 Jun 16;184:139-50. PubMed: 21477639PAPER Brambilla D, Le Droumaguet B, Nicolas J, Hashemi SH, Wu LP, Moghimi SM, Couvreur P, Andrieux K
Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues.
Nanomedicine. 2011 Oct;7(5):521-40. PubMed: 21477665PAPER Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE, Trojanowski JQ, Shaw LM, Decarli CS, Carmichael O, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR,
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.
Brain. 2011 May;134(Pt 5):1479-92. PubMed: 21478184PAPER Kas A, de Souza LC, Samri D, Bartolomeo P, Lacomblez L, Kalafat M, Migliaccio R, Thiebaut de Schotten M, Cohen L, Dubois B, Habert MO, Sarazin M
Neural correlates of cognitive impairment in posterior cortical atrophy.
Brain. 2011 May;134(Pt 5):1464-78. PubMed: 21478188PAPER Esteve P, Sandonìs A, Cardozo M, Malapeira J, Ibañez C, Crespo I, Marcos S, Gonzalez-Garcia S, Toribio ML, Arribas J, Shimono A, Guerrero I, Bovolenta P
SFRPs act as negative modulators of ADAM10 to regulate retinal neurogenesis.
Nat Neurosci. 2011 May;14(5):562-9. PubMed: 21478884Current Filters
No filters selected